• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

作者信息

Chow Victor A, Gopal Ajay K, Maloney David G, Turtle Cameron J, Smith Stephen D, Ujjani Chaitra S, Shadman Mazyar, Cassaday Ryan D, Till Brian G, Tseng Yolanda D, Warren Edus H, Shustov Andrei R, Menon Manoj P, Bhark Sandra, Acharya Utkarsh H, Mullane Erin, Hannan Lindsay M, Voutsinas Jenna M, Gooley Ted A, Lynch Ryan C

机构信息

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Seattle Cancer Care Alliance, Seattle, Washington.

出版信息

Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.

DOI:10.1002/ajh.25505
PMID:31056762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6776079/
Abstract
摘要

相似文献

1
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.CD19特异性嵌合抗原受体T细胞疗法治疗后患有大B细胞淋巴瘤及疾病进展患者的结局。
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
2
Late Events After CD-19 CAR-T Treatment.CD-19嵌合抗原受体T细胞（CAR-T）治疗后的晚期事件
Biol Blood Marrow Transplant. 2020 Jan;26(1):e1-e2. doi: 10.1016/j.bbmt.2019.10.020. Epub 2019 Oct 25.
3
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
4
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.循环抗CD19嵌合抗原受体T细胞（CAR-T细胞）的动力学及其亚群对弥漫性大B细胞淋巴瘤（DLBCL）患者预后的影响。
Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.
5
CAR T cell therapy for B-cell lymphomas.用于B细胞淋巴瘤的嵌合抗原受体T细胞疗法。
Best Pract Res Clin Haematol. 2018 Jun;31(2):135-146. doi: 10.1016/j.beha.2018.04.001. Epub 2018 Apr 11.
6
Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).口吃作为嵌合抗原受体T细胞相关脑病综合征（CRES）的首发症状。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1917-1918. doi: 10.1007/s00432-018-2818-y. Epub 2018 Dec 11.
7
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.弥漫性大B细胞淋巴瘤的第二轮抗CD19嵌合抗原受体T细胞疗法：持续治疗何时能取得成效。
Leuk Lymphoma. 2024 Jun;65(6):868-871. doi: 10.1080/10428194.2024.2325188. Epub 2024 Mar 5.
8
CAR T-cell therapy in refractory large B-cell lymphoma.嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤。
Lancet Oncol. 2018 Jan;19(1):e19. doi: 10.1016/S1470-2045(17)30928-2. Epub 2017 Dec 14.
9
[CAR-T cells in lymphomas: Current and evolving role].[嵌合抗原受体T细胞在淋巴瘤中的作用：现状与发展]
Bull Cancer. 2021 Oct;108(10S):S28-S39. doi: 10.1016/j.bulcan.2021.04.022.
10
Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.开放获取？扩大嵌合抗原受体（CAR）疗法在急性淋巴细胞白血病（ALL）中的可及性。
Exp Hematol. 2018 Oct;66:5-16. doi: 10.1016/j.exphem.2018.07.002. Epub 2018 Jul 20.

引用本文的文献

1
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.原发性难治性和复发性弥漫性大B细胞淋巴瘤的治疗前景：最新进展与新兴疗法
J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.
2
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.抗CD19嵌合抗原受体T细胞疗法后复发/难治性弥漫性大B细胞淋巴瘤患者中，探索程序性死亡受体1抑制剂/程序性死亡受体1抑制剂联合化疗作为挽救治疗的起始时间及患者选择
Cell Transplant. 2025 Jan-Dec;34:9636897251338713. doi: 10.1177/09636897251338713. Epub 2025 Jun 5.
3
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.复发/难治性大B细胞淋巴瘤中CAR T细胞治疗失败后双特异性抗体治疗的结果
Blood Adv. 2025 Aug 12;9(15):3955-3966. doi: 10.1182/bloodadvances.2024015719.
4
Be cautious to adopt a second CAR T-cell infusion after failure of CD19/CD22 cocktail CAR T-cell therapy in relapsed/refractory B-NHL.在复发/难治性B细胞非霍奇金淋巴瘤（B-NHL）中，CD19/CD22联合嵌合抗原受体（CAR）T细胞疗法失败后，谨慎采用第二次CAR T细胞输注。
Cancer Immunol Immunother. 2025 Mar 22;74(5):156. doi: 10.1007/s00262-025-04001-7.
5
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.在接受CAR T细胞治疗后进展的复发/难治性弥漫性大B细胞淋巴瘤中，odronextamab单药治疗：ELM-1研究的初步分析
Blood. 2025 Apr 3;145(14):1498-1509. doi: 10.1182/blood.2024027044.
6
Afatinib boosts CAR-T cell antitumor therapeutic efficacy via metabolism and fate reprogramming.阿法替尼通过代谢和命运重编程增强 CAR-T 细胞抗肿瘤治疗效果。
J Immunother Cancer. 2024 Nov 17;12(11):e009949. doi: 10.1136/jitc-2024-009949.
7
Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.在嵌合抗原受体 (CAR) T 细胞治疗后复发/进展的大 B 细胞淋巴瘤患者中，有几个可以在细胞给药前确定的预测其预后的因素。
Cancer Med. 2024 Sep;13(17):e70138. doi: 10.1002/cam4.70138.
8
The basic biology of NK cells and its application in tumor immunotherapy.自然杀伤细胞的基础生物学及其在肿瘤免疫治疗中的应用。
Front Immunol. 2024 Aug 16;15:1420205. doi: 10.3389/fimmu.2024.1420205. eCollection 2024.
9
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.接受或不接受放疗桥接的复发/难治性 B 细胞 NHL 患者和局限性（<5 个部位）前 CART 疾病患者的结局。
Blood Adv. 2024 Sep 24;8(18):4877-4885. doi: 10.1182/bloodadvances.2024013647.
10
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.CD19嵌合抗原受体T细胞（CART）治疗失败后，采用挽救性CD20-SD-CART疗法治疗侵袭性B细胞淋巴瘤。
Front Oncol. 2024 Jun 25;14:1376490. doi: 10.3389/fonc.2024.1376490. eCollection 2024.

本文引用的文献

1
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
2
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
3
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
4
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
5
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.弥漫性大B细胞淋巴瘤患者自体干细胞移植后复发的结局：CORAL研究纳入患者的分析
Bone Marrow Transplant. 2017 Feb;52(2):216-221. doi: 10.1038/bmt.2016.213. Epub 2016 Sep 19.
6
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.